KROS
Keros Therapeutics Inc
NASDAQ: KROS · HEALTHCARE · BIOTECHNOLOGY
$11.12
+0.18% today
Updated 2026-04-30
Market cap
$228.75M
P/E ratio
5.03
P/S ratio
0.94x
EPS (TTM)
$2.30
Dividend yield
—
52W range
$10 – $23
Volume
0.4M
Keros Therapeutics Inc (KROS) Financial statements
SEC filings — annual and quarterly data.
Profit margin
35.60%
Operating margin
-7,577.00%
ROE
19.90%
ROA
9.25%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2018 | $10.00M | $-1.33M | -1.11% | -16.91% | -13.35% |
| 2019 | $10.00M | $-12.34M | -73.48% | -105.63% | -123.44% |
| 2020 | $2.50M | $-45.36M | -24.20% | -1,866.28% | -1,814.44% |
| 2021 | $20.10M | $-58.74M | 100.00% | -280.46% | -292.26% |
| 2022 | $20.00M | $-104.68M | -8.08% | -573.95% | -523.40% |
| 2023 | $151000.00 | $-152.99M | 100.00% | -112,543.71% | -101,319.21% |
| 2024 | $3.55M | $-187.35M | 100.00% | -5,938.96% | -5,277.55% |
| 2025 | $244.06M | $87.01M | 99.38% | 28.94% | 35.65% |